Clean Yield Group Lowers Stock Position in Organon & Co. (NYSE:OGN)

by · The Markets Daily

Clean Yield Group decreased its stake in Organon & Co. (NYSE:OGN – Free Report) by 3.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 112,698 shares of the company’s stock after selling 3,991 shares during the quarter. Clean Yield Group’s holdings in Organon & Co. were worth $1,681,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Prospera Private Wealth LLC bought a new position in Organon & Co. in the third quarter valued at $25,000. William B. Walkup & Associates Inc. purchased a new position in shares of Organon & Co. during the 2nd quarter valued at about $31,000. Versant Capital Management Inc lifted its position in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after buying an additional 1,324 shares during the last quarter. Abich Financial Wealth Management LLC boosted its stake in Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after buying an additional 2,315 shares in the last quarter. Finally, Trust Co. of Vermont grew its position in Organon & Co. by 109.4% during the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after acquiring an additional 1,372 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 1.5 %

Organon & Co. stock traded down $0.24 during trading hours on Monday, reaching $15.61. The stock had a trading volume of 1,463,003 shares, compared to its average volume of 2,961,651. The company has a fifty day simple moving average of $15.36 and a 200-day simple moving average of $18.37. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The stock has a market cap of $4.02 billion, a PE ratio of 3.10, a PEG ratio of 0.81 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN – Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the prior year, the firm earned $0.78 EPS. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. Analysts forecast that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.17%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Wall Street Analyst Weigh In

Separately, Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

View Our Latest Analysis on Organon & Co.

About Organon & Co.

(Free Report)

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

See Also

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).